References:
  1. Schiopu SRI, Käsmann L, Schönermarck U, Fischereder M, Grabmaier U, Manapov F, Rauch J, Orban M. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report. Transl Lung Cancer Res. 2021 Feb;10(2):1039-1046. doi: 10.21037/tlcr-20-1095. Erratum in: Transl Lung Cancer Res. 2021 Jun;10(6):3029. PMID: 33718042; PMCID: PMC7947381.
  2. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 2019; 5(9): 1310–1317.
  3. Ganatra S and Neilan TG. Immune checkpoint inhibitorassociated myocarditis. Oncologist 2018; 23: 879–886.
  4. Cho JH. Immunotherapy for non-small-cell lung cancer: Current status and future obstacles. Immune Netw 2017. 17(6):378–391. doi:10.4110/in.2017.17.6.378
  5. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med 2016. 14:73. doi:10.1186/s12916-016-0623-5.
  6. Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint inhibitor–associated myositis: Expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018. 138:743–745. doi:10.1161/CIRCULATIONAHA.118.035898.
  7. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001. 291(5502):319–22. doi:10.1126/science.291.5502.319.
  8. Zhang L, Jones-O’Connor M, Awadalla M, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Treat Options Cardiovasc Med 2019. 21(7):32. doi:10.1007/s11936-019-0731-6.
  9. Weber JS, Dummer R, De Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013. 119(9): 1675–82. doi:10.1002/cncr.27969.
  10. Mahmood SS, Fradley MG, Cohen JV., et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol2018. 71(16):1755–1764. doi: 10.1016/j.jacc.2018.02.037/.